Delving into the Latest Updates on TQB3456 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

TQ B3456, TQ-B3456, TQB-3456

Target

EGFR

Mechanism

EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication-

Inactive Indication

Non-Small Cell Lung Cancer

Originator Organization

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active Organization-

Inactive Organization

Centaurus Biopharma Co Ltd

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价TQB3456片在中国非小细胞肺癌患者中的安全性和耐受性，确定最大耐受剂量（MTD）和剂量限制性毒性（DLT）。次要目的评价TQB3456片在非小细胞肺癌患者中的药代动力学特征；评估TQB3456片的初步抗肿瘤疗效，为后续临床研究推荐合适的用药剂量和给药方法。

[Translation]

Primary objective: To evaluate the safety and tolerability of TQB3456 tablets in Chinese patients with non-small cell lung cancer, and to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). Secondary objective: To evaluate the pharmacokinetic characteristics of TQB3456 tablets in patients with non-small cell lung cancer; To assess the preliminary anti-tumor efficacy of TQB3456 tablets, and to recommend appropriate dosage and administration methods for subsequent clinical studies.

Start Date20 Jul 2018

Sponsor / Collaborator

Centaurus Biopharma Co Ltd

[+1]

100 Clinical Results associated with TQB3456

Login to view more data

100 Translational Medicine associated with TQB3456

Login to view more data

100 Patents (Medical) associated with TQB3456

Login to view more data

100 Deals associated with TQB3456

Login to view more data